Ambrilia Biopharma Inc. Presents Latest Data on its Novel HIV Integrase Inhibitors at the 47th ICAAC

MONTREAL, QUEBEC--(MARKET WIRE)--Sep 18, 2007 -- Ambrilia Biopharma Inc. (Toronto:AMB.TO - News) presented today new data on its novel series of HIV integrase inhibitors (pyrazolopyridine inhibitors), showing their potential synergies with some of the known integrase inhibitors (diketo acid inhibitors) currently in clinical development. Furthermore, Ambrilia's pyrazolopyridine inhibitors bind to a different site on the HIV integrase enzyme from that of the known competitive active site inhibitors such as the diketo acid derivatives, suggesting a different mechanism of strand transfer inhibition. The poster entitled "Pyrazolopyridine Compounds as Novel HIV-1 Integrase Inhibitors" was presented by Dr. Jinzi Wu, Vice-President, Preclinical and Basic Research, Ambrilia, at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy ("ICAAC") held in Chicago (September 17-20).